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PART A: THE PROGRESSION OF A CATALYTIC IMMUNE RESPONSE




THE UNIVERSITY OF TEXAS AT AUSTIN, 1994
SUPERVISORS: BRENT L. IVERSON and JONATHAN L. SESSLER
Part A: This thesis describes the first detailed study of
how a catalytic immune response matures over a series of
immunizations. Specifically, three male New Zealand White rabbits
were immunized with a 4- (carboxy) benzyl phenyl phosphate hapten
conjugated to keyhole limpet hemocyanin (KLH) . The three rabbits
received an initial immunization with the immunogen, followed by
three immunizations at three week intervals. Serum samples were
obtained from each rabbit ten days following every immunization.
Pure polyclonal IgG antibodies were obtained by a multiple step
VI 1

isolation and purification process. The catalytic activity of each
sample was demonstrated by the rate enhancement and catalytic
efficiency of the hydrolysis of the corresponding carbonate
substrate. The results show a remarkable similarity in the immune
response maturation seen in two of the three rabbits. The third
rabbit was diseased and lagged slightly behind. Through the four
immunizations, the immune response continued to optimize due to an
apparent increase in the affinity of the polyclonal antibodies.
This is quite significant, in that it provides the first
experimental evidence that affinity maturation is important for
antibody catalysis. We have thus begun to shed the first rays of
light inside the black box that produces catalytic antibodies.
Part B: A novel sapphyrin-functionalized silica gel has
been used to study the anionic binding properties of the expanded
porphyrin sapphyrin. The preparation of the first generation of
this type of support is discussed. The silica-bound sapphyrin
displayed longer retention times under neutral, isochratic HPLC
conditions, for molecules with sterically accessible oxyanions. In
particular, the sapphyrin-functionalized silica gel showed a
remarkable preference for arsonates and phosphates. Furthermore,
mixtures of nucleotides and oligonucleotides were cleanly separated
according to the number of phosphate units they possessed. Thus,
not only does sapphyrin-bound silica gel provide an exquisite way
vui

to investigate anion binding specificities of sapphyrin, it also
provides a viable method to selectively separate and analyze anion
types. These types of modified silica gels may be useful for
solving present day environmental problems, as well as separating
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A: Research Objectives and Aims
The primary objective of this project is to investigate how
the catalytic activity of an elicited immune response matures over
the course of an immunization regimen. Changes in catalytic
parameters and apparent catalytic antibody affinity will be
correlated in polyclonal antibody samples isolated after each of
four immunizations. In particular, vmax , km , kca t, catalytic
efficiency, titer, rate enhancement, and catalytic fraction shall
be evaluated. This work is important because it will elucidate for
the first time when optimal catalytic activity is produced by the
immune system. Moreover, watching catalytic activity evolve will
provide insight into the fundamental processes involved.
In other words, this research will expand our understanding
of how the catalytic immune response optimizes, and whether it is
dependent on genetics or hapten structure. The understandings we
gain will enable us to optimize the catalytic efficiency of other
polyclonal systems and refine the focus of other important research
in our lab. In addition, this research will provide valuable
building blocks for investigating the feasibility of immunization
based therapies and treatments for a wide range of conditions.
A final point worth making is that it is not obvious that the
immune system should be capable of producing and/or optimizing
catalytic antibodies. The immunization of animals with a hapten or

immunogen simply results in the production of hapten specific
antibodies. Over the course of the immunization regimen, the
affinity of these antibodies increases, resulting in tighter
binding of antibody to hapten. What we have discovered through the
following studies is that it is this increase in affinity for the
hapten that results in increased catalysis. Thus, we now know that
the immune system efficiently evolves catalytic activity, whether
it wants to or not.

A: Background and Significance
Immune Response. The humoral immune response in
vertebrates is mounted to counter bacterial infections,
extracellular phases of viral infections, and antigens (1) . This
process is controlled by a collection of proteins known as
immunoglobulins or antibodies. The antibodies are produced by B
lymphocyte cells found primarily in the bone marrow and spleens of
mammals
.
An antigen can be a protein, polysaccharide, lipoprotein, or
nucleoprotein (2) . To be an antigen, a macromolecule must possess
both antigenicity and immunogenicity . Immunogenicity is the ability
of a molecule to present itself to the immune system as foreign
(i.e. nonself ) . Therefore, the low molecular weight haptens can
actually bind to antibodies, but they cannot by themselves
stimulate antibody production. They are attached to some type of
carrier protein for immunization. Antigenicity describes the
ability of the antigen to bind with specificity to an antibody.
Antibodies. Antibodies are unique proteins that bind
selectively to their target molecule, or antigen (2). Antibodies
are composed of two identical light chains and two identical heavy
chains. The chains are bound together by disulfide linkages. Each




carboxy-terminal constant region (C) . The class of antibody is
defined by the heavy chain C region (1)
.
Antibodies have a two-fold mission. Not only do they bind
antigens, but they also carry out certain immunological effector
functions. Different domains on the antibody perform these tasks.
The Fc region carries out the effector functions. The antigen
binding fragment (Fab) is where the binding pocket is located. The
binding pocket is formed by the hypervariable regions of the heavy
and light chains. It is quite remarkable to find out that the few
hundred genes of the mammalian immune system are capable of
producing as many as 10^ different antibody specificities.
Five major classes of immunoglobulins (Ig's) perform various
functions during immune responses. The five classes are IgM, IgG,
IgD, IgE, and IgA. When a foreign antigen is introduced into an
animal, IgM is produced and released into the serum the first 2 to
3 days. IgG production begins 2 to 3 days after the IgM, and is
released into the blood and the interstitial fluids. The IgG
molecule has an average mass of 155 kD. It is the IgG that
dominates in the later stages of the immune response, and this is
the type of antibody we will be primarily concerned with.
The Origin of Diversity in the Immune Response. There
has been a historic debate about exactly how the tremendous
diversity seen in the immune response is created. At one extreme,
is the older belief that an individual inherits all the necessary

tools to respond to all antigens. This is called the germ line
theory. A newer idea is that the individual inherits some genes
dealing with antibody specificity and generates diversity through
somatic mutations, called the somatic recombination theory. The
germ line theory argues that the germ line transmits all the genes
necessary to create all specificity. This would mean that all the
genes for encoding the variable regions are present in the cell.
Theoretically, this could account for some 10^ specificities.
Recent experimental evidence has suggested that this is not the
whole story.
The somatic mutation theory argues that there is no
evolutionary pressure for novel genetic combinations to survive,
especially since responses to certain antigens have no survival
value to the individual. The amount of genetic material that would
need to be passed on would be far too large to be plausible. The
somatic recombination theory holds that only a minimum of germ-line
genes are passed on. The extremely diverse specificity actually
results from somatic mutations of these genes during maturation of
antibody producing cells. It is now widely held that somatic
mutation is required to produce the high affinity antibodies that
are predominant at the end of an immune response.
Clonal Selection. A widely accepted paradigm is the Clonal
Selection Theory, which was originally proposed by Burnet (3-7).
This theory states the antigen does not instruct the immune system

in what specificity is needed; rather it contacts an appropriate
receptor. This contact then stimulates production and proliferation
of clones of the most reactive cells. High affinity antibodies will
bind most tightly, and if the antigen is present in a relatively
small quantity, the high affinity antibodies will dominate the
response. However, if there is a relatively high concentration of
antigen, then low, medium, and high affinity antibodies may all be
released during the immune response. After immunization, the level
of antigen in the system slowly decreases, allowing only higher
affinity receptors to be contacted, thus stimulating production of
high affinity antibodies.
Heterogeneity of the Immune Response. There have been
several early studies to demonstrate the heterogeneity of the
affinities seen in the antibodies produced early in an immune
response (8-13). The studies showed that even simple antigens
initially produced a wide range of affinities in antibodies. The
distribution of antibodies as determined by equilibrium dialysis
and fluorescence quenching appeared to be Gaussian or Sipsian (14-
16). These functions both represent very similar symmetric
distributions of affinities. The term heterogeneity index is used
to describe this spread of the normal distribution curve of
affinities
.
Eisen and Siskind were the first to demonstrate the diversity
in antibody affinity. They immunized a rabbit with 2,4-

dinitrophenyl-bovine gamma-globulin (DNP-BGG) . The antibodies were
isolated and separated by fractional precipitation. The ten
fractions of antibodies obtained showed a 10,000 fold difference in
association constants (17) .
Maturation of the Immune Response. There is an antibody
class shift seen as the immune response matures. The initial immune
response consists of IgM, with a rapid shift to IgG during the
primary response. Later responses will be almost entirely IgG.
There is also a concomitant refinement in the affinity of IgG
antibodies. This results from increased production of the highest
affinity antibodies (4)
.
A number of early researchers reported a progressive change
in antibody affinity as the immune response progressed (9,18-26).
Eisen and Siskind were able to show that rabbits immunized with
DNP-BGG showed a marked increase in affinity of their antibodies as
the immune response matured (17,27). The results are shown in Table
1. Similar results were obtained in guinea pigs immunized with the
DNP-BGG antigen (28). Comparable results were also obtained with
different antigens and varying haptenic determinants (18,29-31),
and in one study similar results were seen with horses (32)
.
Steiner and Eisen were also able to show that a change in
antibody structure is seen as the immune response matures (33)
.
Using the B cells from immunized rabbits, they were able to prove
antibodies produced later in the immune response had a higher





that the amino acid sequence of the anti-DNP antibodies produced
early and late in the immune response differed (34). Later,
Bernstein was able to compare the peptide maps of the Fab fragments
of anti-DNP antibodies by fractionation (35). The maps were
similar, leading him to conclude the differences seen by McGuigan









0.05 9.88 (3) 10.0 (9) 11.1 (8)
0.5 8.72 (6) 10.3 (7) 11.2 (7) 12.7 (7)
5.0 8.96 (17) 9.70 (8) 10.2 (5) 11.0 (5)
50.0 8.46 (6) 8.06 (5) 8.52 (5) 9.54 (4)
Table 1. Maturation of affinity in rabbits immunized with DNP-
BGG. Affinity is given in kcal/mol. Affinity was measured by
fluorescence quenching (27). The number in parenthesis represents
the number of rabbits used in each experiment.
The maturation of the immune response may be the result of
one of two processes. The first possibility is that a large
percentage of antigen early in the immunization binds to the high
affinity antibodies resulting in removal of high affinity
antibodies from the serum. This also implies the antibodies
produced earlier and later in the response are the same. The second
possibility is that high affinity antibodies are produced in larger
quantities as the response progresses.

Current Model for Immune Response Maturation. The
current model for maturation of the immune response, as pertaining
to antibody affinity, can be summarized as follows. The existing
antibody producing cells compete for the antigen present in
solution. As the amount of antigen decreases, the probability of it
encountering only higher affinity receptors increase. This would
result in the proliferation of higher affinity antibodies as the
lower affinity receptor cells become less capable of binding
antigen. The lower affinity cells would be unsuccessful in
capturing antigen, and thus not be stimulated to reproduce. The
lower affinity cells would eventually be killed off by the more
"fit" high affinity cells.
Kinetics of the Immune Response. The first time an
individual contacts an antigen the response seen is called the
primary response (Figure 1) . The second encounter is called the
secondary response. It is nearly identical to the primary response
except the latent period is much shorter, and the magnitude of the
response is much greater.
In the primary response, there is an initial latent phase in
which no antibody is detected. The subsequent production occurs at
an exponential rate, and thus is termed the log phase. Next, there
is a phase of constant production called the plateau phase. This is





Figure 1. Kinetics of primary and secondary immune responses.
Monoclonal vs. Polyclonal Antibodies. Antibodies can be
classified into two categories, monoclonal antibodies and
polyclonal antibodies. Antibodies obtained directly from serum are
referred to as polyclonal antibodies and represent the entire
distribution of antibodies present in the serum at any one time.
Monoclonal antibodies are the most common type of catalytic
antibody studied. They are obtained by immunizing an animal with
the antigen (hapten) of interest. Once the proper level of immune
10

response is achieved, usually determined by titer, lymphocytes (B
cells) are harvested from the animal. The lymphocytes are then
immortalized by cell fusion with immortal myeloma cells. The clones
of the resulting hybrid-myeloma, or hybridoma, are allowed to
synthesize the lymphocyte's immunoglobulins. The monoclonal method
produces strictly homogenous pools of antibodies. This aids in the
classification and determination of the mechanism of catalysis.
Catalytic Antibodies. Catalytic antibodies are elicited
from an animal through immunization with a chemical hapten that
closely mimics a high energy intermediate or transition state for a
desired reaction (36-41). The antibodies that are obtained from the
animal serum presumably contain binding pockets that selectively
bind the substrate. They bind in such a manner as to lower the
overall transition state energy and catalyze the reaction. Thus, it
is important to design transition analogs that closely mimic the
transition state in every possible chemical structural feature.
Monoclonal Catalytic Antibodies. There have been
several approaches using monoclonal antibodies to achieve
catalysis. These approaches have included the use of geometry
complimentarity (42-47), charge complimentarity (48,49), catalytic
cofactors (50-54), medium effects (55-57), and proximity of two
simultaneously bound substrates (58-63)
.
There are a wide variety of reactions that have been
catalyzed using monoclonal antibodies. Some of the more common
11

reactions catalyzed include ester hydrolysis (36,56,57,64-68),
amide hydrolysis (57,69), rearrangements (70), carbonate hydrolysis
(37,71), lactonization (42), amide synthesis (61,62), and trans-
esterification (56,57,63,72). There are also examples of antibodies
catalyzing Diels-Alder reactions (58-60) , Claisen rearrangements
(43-45), olefin isomerization (73), a P-elimination (74), an
asymmetric ketone reduction (54), phosphate hydrolysis (75), and
even a photochemical cleavage reaction (76)
.
Monoclonal vs. Polyclonal Catalytic Antibodies. Using
monoclonal antibodies to study antibody catalysis has allowed
individual catalysts and catalytic mechanisms to be studied.
However, there are several serious limitations to using the method
of monoclonal antibodies. What we end up seeing is a very limited
view of the overall immune response, since only a few of the
antibodies actually produced by the immune response are analyzed.
The randomness of this method may allow for selection of an
antibody with characteristics not representative of the entire
immune response. Therefore, this method fails to allow for a
systematic study into hapten design and the maturation of the
immune response.
Put another way, using monoclonal methods for the study of
catalytic antibodies is analogous to trying to find the proverbial
needle in a haystack. Nothing is known about how the immune system
creates the best catalysts. If one is fortunate enough, one might
12

sit on the needle on the first attempt. This is not likely, so one
must then enlist the help of others, buy detection equipment, fund
an environmental impact study, and expend countless hours and
resources trying to find a needle which may or may not exist.
In an era of shrinking research resources, one can clearly
see that a method that gives us greater access to the big picture
of the immune response should be further developed. This method is
catalytic polyclonal antibodies. Polyclonals will allow us to
uncover important trends in the overall immune response. One can
then study the maturation of this response over a series of
immunizations, as well as study basic trends relating hapten
structure to catalytic activity. The only potential drawback in
using polyclonal catalytic antibodies is that one casnnot look at
the individual antibody ctructure and mechanism. This will continue
to require the use of hybridomas.
An entire polyclonal study using rabbits may take as little
as 4 months from design to conclusion. The cost and manpower
requirements are minimal and allow for several studies, using
several animals, to be conveniently carried out. On the other hand,
use of monoclonal antibodies can take two to three times as long,
requiring several additional time consuming processes. Thus, one is
easily convinced that polyclonal catalytic antibody studies can be
used to provide us with an understanding of how the entire immune
system responds to varying haptenic determinants, at a substantial
13

saving in resources. The results obtained will provide invaluable
insight into the relationship between various parameters as the
immune system matures, while allowing us to design hapten systems
that optimize overall antibody catalytic activity.
Catalytic Polyclonal Antibodies. There have been
several attempts to investigate catalytic activity in polyclonal
sera. There was an early attempt to produce polyclonal catalytic
antibodies that could catalyze a Schiff base formation (77) . There
was no rate enhancement detected in the polyclonal antibodies that
were produced. A later study showed polyclonal antibodies that
catalyzed ester hydrolysis, but the results were not reproducible
(78). Another study claimed enhancement of steroidal ester
hydrolysis by immunization with the reaction product (79)
.
Recently, Gallacher et al . reported the isolation of
polyclonal catalytic antibodies from the sera of sheep (80) . The
sheep polyclonal antibodies showed rate enhancement for the
hydrolysis of the carbonate substrate 2, shown in Figure 2, after a



















Figure 2. Carbonate substrate and phosphate hapten used in the
Gallacher study.
Recent research within the Iverson group has provided
substantial advancements in the field of polyclonal catalytic
antibodies (81-84). The initial study, which was carried out by
Stephens, involved catalyzing the hydrolysis of the triphenylmethyl
ether (trityl) substrate 4. This substrate showed a minimal
background rate and allowed comparison with a previous monoclonal




























The triaryl phosphonium ion hapten 3 was used as a transition
state analog for the trityl substrate 4. The positive charge in the
hapten emulates the positive charge seen in the acid catalyzed
hydrolysis of the trityl substrate 4. The polyclonal antibodies
should stabilize the positive charge of the protonated substrate
through charge complimentary in the antibody binding pocket,
catalyzing hydrolysis of the trityl substrate. This is comparable
to what was observed in the analogous monoclonal study. The
monoclonal study showed a rate enhancement (kcat/kuncat) of 270.
This initial trityl hydrolysis study was a test platform of
some important ideas. In addition to showing the potential of
polyclonal antibodies to probe weak, catalytic activity, it also
showed reproducibility.
The next study consisted of five heterozygous New Zealand
white rabbits being immunized five times with the hapten 3.
Polyclonal antibodies were purified from the sera collected prior
to and after a series of immunizations. There was no catalytic
activity present in the serum, or "prebleed, " obtained prior to the
first immunization.
After the last immunization, polyclonal IgG antibodies were
isolated and studied in depth for catalytic activity by Stephens
and myself. Catalysis studies of the polyclonal antibodies from the
five rabbits showed results consistent with Michelis-Menten
kinetics. The lack of significant variability in the kinetic
17

parameters analyzed was remarkable (see Table 2), considering that
the immune system presumably chooses antibodies based on binding to










/ • -In(min )
App kcat/
kuncat
1 37 .19 .03 190
2 5 .19 .06 380
3 70 .05 .03 190
4 31 .28 .02 125
5 93 .19 .02 125
Table 2. Polyclonal catalytic variability in 5 rabbits immunized
with the same hapten.
The phosphonium hapten 3 was also used as an antigen for five
mice (83) . Polyclonal IgG antibodies were isolated from the
combined sera. Analysis of the polyclonal antibodies showed a
catalytic activity with an apparent kcat of 0.02/min. This compares
favorably with the average kcat of 0.03/min seen in the 5 rabbits.
It is quite interesting to compare the rate enhancements
between the monoclonal and polyclonal antibodies obtained to the
phosphonium hapten. The murine monoclonal antibody 37C4 showed a
rate enhancement of 270 for the hydrolysis of the trityl substrate,
while the polyclonal antibodies isolated from the animals immunized
with the same hapten showed an apparent rate enhancement of 125 to
380. This result indicates that the same qualitative answer was
generated using polyclonal antibodies at a substantial reduction in
























Figure 4. Phosphate and phosphorothioate hapten structures used




Another study, by Wilmore of the Iverson group, showed
catalysis of carbonate esters was possible (82). The catalytic
activity was obtained using both a phosphate and phosphorothioate
hapten (Figure 4). The mechanism of carboxylic acid derivative
hydrolysis is shown in Figure 5 (85) . The phosphate hapten showed a
rate enhancement of 1800, as compared to 680 for the
phosphorothioate hapten. This is in line with the rate enhancements
of 800 to 10,000 for carbonate ester hydrolysis by various
monoclonal antibodies (37,41,71). Once again, a polyclonal antibody
study was able to show the same basic results in the catalysis of
carbonate ester hydrolysis as monoclonal antibodies. The study also
proved that the phosphate hapten was a better mimic of the











Figure 5. Carboxylic acid derivative hydrolysis
To briefly summarize the significant findings with catalytic
polyclonal antibodies:
1. The polyclonal catalytic antibodies isolataed from animals
of the same species are shown to possess similar catalytic
activity when immunized with the same hapten.
21

2. The results shown to date by polyclonal antibody studies
provide the same conclusions as analogous monoclonal studies.
It should again be emphasized that the polyclonal studies
provide the results in a much quicker and much less
demanding manner, while saving precious research resources.
3. Monoclonal studies focus primarily on the mechanistic
aspects and selectivity of antibody catalysis. Polyclonal
studies can provide us with general and systematic
conclusions concerning how differences in hapten structure
affect catalytic activity.
4. The most significant point to be made is catalytic
polyclonal antibodies represent a composite of the entire
response.
Chemical Kinetics. Central to this project is the
assumption that over the course of the immunization regimen the
affinity of the polyclonal antibodies for the hapten will increase.
As already presented, this has been established through numerous
earlier immunological studies.
To better understand how polyclonal catalytic antibodies are
able to catalyze reactions, a brief review of chemical kinetics is
in order. The fundamentals for this discussion result from the
Transition State Theory first proposed by Eyring in the 1930' s (1).
22

If one considers the basic substrate (S) reaction catalyzed by the
antibody (Ab) to be:
ki k2
Ab + S <-»Ab-S -> Ab + P
k-i
In this case, there is actually a more complex situation that
involves two transition states and a tetrahedral intermediate. It
will be assumed the antibody-tetrahedral intermediate activated
complex lies at an energy saddle point on the reaction coordinate
(Figure 6). The energy of activation is often referred to as AG*,
or the Energy of Activation. Proceeding from one point in the
immunization regimen to the next, the energy barrier will undergo
changes as the antibody affinities change. The change in affinity
for the substrate will result in a change in the energy of the
antibody-substrate complex, or AG^b-S. A change in affinity for the
tetrahedral intermediate will result in a change in energy of the
tetrahedral intermediate-antibody complex, or AG^b-TI
•
Catalytic antibodies are thought to catalyze reactions by
increasing the stabilization of the transition state over the
initial or ground state of substrate. It is important to remember
that we immunize with a phosphate hapten, which mimics the charge
and structure of the tetrahedral intermediate more closely than the
same parameters of the substrate.
The rate enhancement realized by the reaction is directly
correlated to the ratio of the stabilization of the transition
23

state, AAGAB-TIf to the stabilization of the substrate, AAGab-S
We assume that for antibodies k_i » k2, therefore:
km= <*2 + k-l)/ ki == Ks + (k-2/ki) == K3




No Antibody.. y^ ^v




With Higher / x. / \/^N \
Affinity Antibody>V ^y \ \
i
AG




i \ AG \V/ \ \ \ ,
f Substrate Binding \ y / \ \ \
AG V / \ \ \
' Substrate Bending \/ \ 1 1
REACTION COORDINATE
Figure 6. Reaction coordinates for a catalyzed reaction
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Table 3 presents an analysis of possible scenarios that occur
upon immunization. The bottom line of this thought experiment is
that in order to see an increase in catalytic activity we must see
an increase in the affinity of antibodies for the tetrahedral
intermediate. This is shown in cases 4, 6, 8, and 10 where AEAb-TI
goes down, and catalytic activity rises.
CASE AGAb-S AGAb-TI Akm Akcat ACatEf
f
1 + + + -
2 + + +
3 + - -
4 + - + + + +
5 - + - - - -
6 - - - +
7 - - -
8 - + +
9
10 - - - - + + +
Table 3. Effects of changing antibody affinities for substrate





The ultimate long range goal of our lab is to be able to
investigate systematically the effect that hapten structures have
on the efficiency of the catalytic polyclonal antibodies produced.
In order to accomplish this, one needs to first understand how the
entire immune system responds and matures when challenged with a
simple hapten-protein conjugate. As stated before, the polyclonal
sample, unlike monoclonal samples, will be representative of the
entire immune response.
The technical advantages of catalytic polyclonal antibodies
are also worth repeating. They require less time from design to
conclusions, cost less, are less manpower intensive, and are
technically easier. Recent studies in our labs have shown us that
there is little variability between different animals of the same
species.
The reaction chosen to be catalyzed was a carbonate
hydrolysis (Figure 7) . These types of reactions are well understood
mechanistically and described in the introduction. The phosphate
hapten 5 was chosen as the hapten for our studies. It should most
closely mimic the tetrahedral intermediate involved with hydrolysis
26

of substrate 6. Gallacher et al. (86,92,93) previously obtained




Figure 7. Phosphate hapten 5 and carbonate substrate 6.
The substrate used was chosen for several reasons. It
possesses aromatic rings, which are necessary for UV detection and
also provide antigenicity (2) . The carbonate substrate 6 used in
his study is also the first in a series of substrates that will be
27

used to probe the effect that slight variations in size and shape




Hapten Synthesis. The phosphate hapten was synthesized by
Wallace in our group according to Figure 8. The first step consists
of converting phosphorous trichloride to the 2-
(trimethylsilyl) ethyl dichlorophosphite, by slow addition of 2-
(trimethylsilyl) ethanol . After work up, the clear residue was then
distilled and the fraction that boiled at 38-40°C collected. The
resulting dichlorophosphite was then reacted with
diisopropylethylamine . Phenol was added, and after work up the
phosphite is converted to the phosphate by using hydrogen peroxide.
The final step was to deprotect the phosphate and the carboxylic
acid.
The phosphate hapten was coupled to the carrier protein
keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA) . The
KLH-hapten conjugates were used in animal immunizations, while the
BSA-hapten conjugate was used in the preparation of ELISA plates.
Substrate Synthesis. The carbonate substrate was
synthesized according to Figure 9. The first step involved coupling
the pentaflourophenyl ester with butylamine. After work up the
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Figure 8. Synthesis of the phosphate hapten 5
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Figure 9. Synthesis of the carbonate substrate 6,
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Immunization Regimen. Serum samples from three male New
Zealand white rabbits were obtained prior to the first
immunization. These samples would be used to show lack of activity
in the serum prior to initial immunization. At this point it was
noted that Rabbit 2335 was experiencing an illness or eating
disorder. Diet was adjusted, although Rabbit 2335 remained
considerably thinner than rabbits 2336 and 2337. A post-mortem
examination will be performed on Rabbit 2335 to determine the exact
cause of this health condition.
The initial injection employed Freund's complete adjuvant
with our antigen. Subsequent injections employed Freund's
incomplete adjuvant. There were four injections at 21 day
intervals. Serum samples were obtained 10 days after each
immunization.
Enzyme Linked Immunosorbant Assay (ELISA) . ELISA was
used to determine qualitatively the amount of hapten specific
antibody present in each whole serum sample.
BLEED # Rabbit 2335 Rabbit 2336 Rabbit 2337
PREBLEED <l/200 <l/200 <l/200
1 <l/200 1/1,200 1/1,536
2 1/4,216 1/11,212 1/27,136
3 1/28,800 1/32,000 1/51,200
4 1/9,600 1/30,720 l/22
f
016
Table 4. Titers of serum samples. Each number represents the





The titer of serum obtained prior to immunization was <l/200,
indicating the absence of hapten specific antibodies. We see in
each case the titer of the animal increases through bleed 3, and
then decreases.
Antibody Isolation and Purification. IgG antibodies
were isolated from each of the five serum samples taken from the
three rabbits. The isolation consisted of a caprylic acid
precipitation, followed by an ammonium sulfate precipitation. Each
sample was then purified by fast protein liquid chromatography
using a Gamma Bind Protein G column. The Protein G column
specifically binds IgG, which can then be eluted off be switching
to a low pH buffer.
The samples were all concentrated by ultrafiltration to
volumes of 0.5 to 1.5 ml. The final protein concentrations are
shown in Table 5.
SERUM SAMPLE Rabbit 2335 Rabbit 2336 Rabbit 2337
mg/ml (|1M) mg/ml (|lM) mg/ml (|1M)
PREBLEED 6.7 (43) 3.4 (22) 19.3 (19)
1 18.2 (117) 15.2 (101) 12.6 (81)
2 6.6 (43) 10.3 (66) 6.7 (43)
12.9 (83)* 14.2 (91.6)*
3 30.1 (194) 11.2 (72) 9.7 (63)
4 29.9 (192) 12.7 (82) 18.7 (121)
9.0 (58)**
Table 5. IgG concentrations. *Indicates a second isolation and
purification were performed from original serum. **Indicates serum
sample was repurified by protein G.
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Background Rate Determination. It was important to
determine the rate of the carbonate hydrolysis in the absence of
catalytic antibodies. The background rate was determined by
allowing a 150 |IM solution of the carbonate substrate in Tris
buffer at 25°C for 2 days. Background rate was also determined in
the presence of the prebleed sera at antibody concentrations (16-19
[1M) used for catalytic assays. The reactions were analyzed by HPLC,
monitoring at 235 nm for product and substrate. Results are given
in table 6.
Sample Conditions *uncat (M/min)
Buffer 6.5 x 10~ 5 (±0.28 x 10" 5 )
With .
1
mg/mL prebleed sera 11.0 x 10~ 5 (±2.4 x 10~ 5 )
With . 5 mg/mL prebleed sera 7.2 x 10~ 5 (±1.5 x 10~ 5 )





8.4 x 10" 5 (±2.3 x 10~ 5 )
Table 6. Background rates.
Prebleed Serum Activity. To verify the lack of catalytic
activity present prior to immunization, catalytic assays using
prebleed serum were conducted. The reactions consisted of 150 \1M
substrate and 16-19 |1M serum, a second set included 16-19 JIM
inhibitor. The reaction was then analyzed by HPLC, monitoring at
235 nm for the precense of product and substrate. The results are
shown in Table 7. There was no rate enhancement or catalytic




2335 1.5 x 10" 8
2335 with/inhibitor 1.9 x 10" 8
2336 4.5 x 10" 8
2336 with/inhibitor 4.1 x 10" 8
2337 4.5 x 10" 8
2337 with/inhibitor 3.4 x 10" 8
Table 7. Prebleed activity.
Theoretical Inhibition Plots. It was desired to prove
the shapes of the inhibition plots we would obtain are similar to
those predicted by the kinetics equations. Using Mathemat ica
Version 2.2, it is possible to solve a series of kinetics equations
and derive a theoretical inhibition plot for a polyclonal sample.
The competing reactions to be concerned with are the antibody
binding with the substrate and going to product, and the antibody
reversibly binding with hapten. These can be represented by the
following equations (1,2):
ki k2
S + Ab <-» AbS -> Ab + P
k_ x
Ab + H -> AbH
From these two equations we derive a series of five equations. The
first four come directly from the two reaction equations.
(1) kH = { [Ab] F x [H] F }/ [AbH]
(2) [S] T = [S] F + [AbS]
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(3) [H] T = [H] F + [AbH]
(4) [Ab] T = [Ab]f + [AbS] + [AbH]
The fifth equation deals with the Michelis constant, k^.
kM = (k_i + k2 )/ ki
It is assumed for catalytic antibodies that k-i » k2 (1,2),
therefore:
kM = k_i/ ki
And the fifth equation follows:
(5) kM = { [Ab] F x [S] F }/ [AbS]
The five equations were used in the Mathematics program to
solve for [AbS] . To further simplify this solution, values were
substituted in based on known parameters from the variability study
done in our labs (84) . The values used were a substrate
concentration of 50 JIM, a km of 50 |1M, and a total antibody
concentration of 6 JIM. The Mathematica program is used to solve the
five equations and yields:
(-2500 + 50 x [AbS]) x [H] T = -15,000 + (5,300 x [AbS]) - (50
[AbS] 2 ) + (5,600 x kH ) - {(15,000 x kH )/[AbS]} - (156 x [AbS] x kH }
+ ([AbS] 2 x kH )
Next, values of hapten concentration, ([H?]), were inserted in from
to 40 JIM, for each value of Kh plugged in. The values substituted
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for KH were 100, 10, 0.99, 0.1, 0.01, 0.001, 0.0001, 0.00001, and
0.000001. The results were then plotted and compared to actual
inhibition plots. The theoretical inhibition plot is shown in
Figure 10. When comparing the theoretical plots to the actual
plots, we can see similarity to the shape of the actual plot, and
-7
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Figure 10. Theoretical Inhibition Plot.
Inhibition Studies. The hapten used for immunization was
shown to be an effective inhibitor of the polyclonal antibodies
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isolated. The samples that showed catalytic activity were inhibited
with the hapten to determine what percentage of the isolated
antibody binding sites are active. The results are shown in Table
8. The percentage of active binding sites appears to decrease
slightly over the course of the immunizations. The individual
inhibition plots are shown in Figure 11.
Rabbit 2335 RABBIT 2336 RABBIT 2337
BLEED 2 N/A 2.0% 8.0%
BLEED 3 3.0% 7.0% 8.0%
BLEED 4 2.5% 4.0% 6.0%




























































Figure lie. Inhibition Plots for Rabbit 2337
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Catalytic Assays. The samples obtained which showed
evidence of catalytic activity were subjected to Lineweaver-Burk
analysis. The antibody concentration was held at a constant
concentration that was predetermined based on an initial check of
activity. The reaction time and concentration were varied to
achieve a conversion to about 20% product. Each data point was
repeated in triplicate, and the inverses of the average velocities
were plotted versus the inverse substrate concentration. These
plots yielded values for km and vmax . The plots are shown in Figure
12. The standard deviation was determined by plotting the three
sets of data for each point separately. The values obtained for km ,
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Figure 12c. Rabbit 2337 LWB plots
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6.8 x 10~ 8
(± 1.8 x 10~ 8 )
21 (±13)
1 . mg/mL
2.3 x 10~ 7







3.3 x 10~ 8
(± 0.4 x 10~ 8 )
44 (±8)
. 5 mg/mL
5.6 x 10~ 8
(1.6 x 10" 8 )
39 (±17)
. 1 mg/mL
7.7 x 10~ 8







6.2 x 10" 8
(± 0.5 x 10~ 8 )
30 (±8)
. 5 mg/mL
6.6 x 10" 8
(± 0.8 x 10~ 8 )
31 (±11)
. 1 mg/mL
6.0 x 10~ 8
(± 0.8 x 10~ 8 )
19 (±7)
. 1 mg/mL
Table 9. Lineweaver-Burk results for the three rabbits.
Since our polyclonal samples are presumably a heterogeneous
mix of catalysts, the values we obtained are then "apparent" values
for the entire antibody population. These results show some
interesting trends. As reported earlier Rabbit 2335 was "sick"
throughout most of the study, and his parameters seem to reflect
this fact. It can be seen that all three rabbits seem to show an
increase in normalized velocity over the course of the 4
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immunizations. It would also appear after a slight rise, their km
values decrease.
Rate Enhancement and Catalytic Efficiency
Determinations. The ultimate goal of the catalysis studies is to
show that the immune system is able to produce efficient catalysts
which can significantly enhance the rate of a reaction. Rate
enhancement is calculated by:
Rate Enhancement = kcat/ kunca t
Where kcat or tne catalytic constant is:
kcat = vmax / [Ab Binding Sites] t
and the concentration of antibody binding sites is:
[Ab Binding Sites] = [Ab (M) ] x 2 x (% Hapten Specific Antibodies)
The catalytic efficiency, or turnover number, is then kca t/
km . The values obtained for the catalytic parameters are given in
Table 10. It was seen that the catalytic constant, kcat, of the
antibody increases over the course of the immunizations as did the
catalytic efficiency. We can see that the catalytic parameters all
increase throughout the immunization regimen, indicating a
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refinement in the antibodies present to those of higher catalytic
activity.






































Table 10. Catalytic parameters for the catalytic samples. *Kca t
determined from after second purification. KCat determined from




Monoclonal vs. Polyclonal Antibodies. This study
supports the feasibility of using catalytic polyclonal antibodies
to investigate the maturation of the immune response. The entire
study took only 4 months from inception to results. This is quite
remarkable when compared to what would have been required for an
analogous monoclonal study of the same scope and magnitude. The
type of study described here will be easily be expanded to study
the effects of slight variations in hapten size, complexity,
stereochemistry, and structure on catalytic activity and
efficiency. Furthermore, the results of these studies will be
representative of the entire immune response, as are those obtained
from this study.
Antibodies are the Cause of Catalysis. It was shown
that the catalytic activity observed was not the result of some
pre-existing antibody or enzyme. By verifying the lack of activity
in the preimmunization samples, it was also shown that the
catalytic activity seen is completely quenched by using the hapten
as an inhibitor.
Serum Titer as Catalytic Indicator. The serum titer is
not the most accurate indicator of catalytic activity. One can see
from Table 11 that while the serum titer peaks and then drops after
the third immunization, the catalytic activity and efficiency
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continue to increase. We also see that the amount of hapten
specific antibody present seems to correlate with the serum titer.
This study seems to indicate that serum titer is representative of
the amount of IgG antibodies present, but not necessarily an
indicator of the quality of the catalytic antibodies.
Rabbit 2335 Rabbit 2336 Rabbit 2337
Preimmunization
Titer <l/200 <l/200 <l/200
Bleed 1
Titer <l/200 1/1,200 1/1,536
Bleed 2












kca t (min ) None detected 0.26 (±0.07) 0.23 (±0.05)
Efficiency None detected 0.013 0.006
Rate Enhance None detected 3,095 2,738
Bleed 3
Titer 1/28,800 1/32,000 1/51,200
_7














kcat (nun ) 0.17 (±0.01) 0.62 (±0.10) 0.75 (±0.1)
Efficiency 0.004 0.016 0.013
Rate Enhance 2,023 7,380 8,928
Bleed 4












-1> 2.5 4.0 6.0
kcat (min ) 0.39 (±0.03) 1.27 (±0.15) 0.78 (±0.07)








Table 11. This t
parameters. Vmax
able is a summary
values normalized
of kinetic and catalytic
to a 1 mg/mL value.
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The importance of this point is that currently monoclonal
antibodies are normally produced from animals showing the highest
hapten specific titer. In our study, the highest kca t and rate
enhancement was seen in rabbit 2, after his fourth immunization.
All rabbits show the highest efficiency after the fourth
immunization. Thus the titer measurement is not the best way to
determine when, and which animal to use for monoclonal antibody
production.
Polyclonal Catalytic Antibody Variability. This study
again reinforces the idea that there is suprisingly little
variability in the polyclonal antibodies produced by different
animals of the same species. In this study Rabbit 2335 seemed to
lag behind in his response. This is most likely a result of the
fact that he was ill at the start of the study, i.e. the immune
system of Rabbit 2335 was most likely preoccupied with some other
problems. The health of Rabbit 2335 will be determined by a post
mortem examination. In the 3 rabbits, after the fourth
immunization, there was a 6 fold difference in vmax , a 3 fold
variation in km , a 3 fold variation in percentage active
antibodies, and a 3.3 fold variation in kca t and catalytic
efficiency. If we exclude the sick rabbit, 2335, we see practically
no variation in vmax , a 3 fold variation in km , and less than a 2
fold variation in kca t and catalytic efficiency. This is in line
with the results seen in our previous studies (91-94) . Once again,
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polyclonal catalytic antibodies are able to provide an accurate
depiction of the entire immune response and are reproducible.
Rate Enhancements. It is quite striking that the rate
enhancements achieved by the polyclonal antibodies are essentially
the same as those achieved by analogous monoclonal systems. Rate
3 4
enhancements of -10 to -10 are consistent with those seen for
similar monoclonal studies using phosphate haptens (41,75,93).
Maturation of the Immune Response. The kinetic and
catalytic parameters obtained in this study are summarized in Table
11. The trends seen in these results indicate that over the course
of the immunization regimen the catalytic efficiency of our
polyclonal sample increases. There are two possible explanations.
One possibility is that we are seeing better catalytic antibodies.
The other possiblity is that we are seeing more of the higher
affinity antibodies.
There have been studies in the past that have definitively
shown non-catalytic-type antibodies display an increase in hapten
affinity over the course of the immunization regimen. Figure 13
represents the results of a study in which multiple rabbits were
immunized with a dinitrophenyl-BGG conjugate (31,86). There were
four groups of multiple rabbits, with each group being immunized
with a varying concentration of the antigen. In each case, the
affinity of hapten specific antibodies increased over the course of
a 6 week period following immunization. A similar study using
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guinea pigs, immunized with the same hapten, showed the same
results. The results are represented in Figure 14 (43) . A
substantial increase in antibody affinity for hapten is seen over
the period of 2 months following immunization. There are numerous







2 3 4 6
WEEKS WEEKS WEEKS WEEKS
Figure 13. The maturation of antibody affinity as seen in rabbits
immunized with 2, 4-dinitrophenyl-BGG. The affinity was measured by
fluorescence quenching with e-DNP-L-lysine . Affinity is in
kcal/mole.
This study shows a definite increase in catalytic efficiency
through the first four immunizations. This study shows that the
immune response is still optimizing after 4 immunizations. There is
also a continued increase in catalytic efficiency.
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Let us look at Rabbit 2337. We see the kca t was 0.23, 0.75,
and 0.78 after the second through fourth immunizations
respectively. The rate enhancement was 2738, 8928, and 9286. This
would seem to indicate the immune response may have reached its
peak. However, we see km , which reflects substrate binding for
catalytic antibodies, decrease to 19 |im, from a high of 58 HM,
which is of limited significance. We also see that catalytic
efficiency has increased from 0.006 after second immunization, to
0.013 after third immunization, to 0.041 after the fourth
immunization. The immune response of Rabbit 2337 is still
optimizing after four immunizations. Thus, as stated in the
introduction, in order to see an increase in catalytic efficiency,
with no corresponding increase in rate enhancement, the only
possible explanation is that there was a similar increase in the
stabilization of both the transition state and the substrate, which
is case 6 of Table 3.
One can infer that our phosphate hapten, with its tetrahedral
geometry and negative charge, accurately mimicked the tetrahedral
intermediate in the hydrolysis of the carbonate substrate. The
closer the hapten mimics the transition state, the higher the
catalytic activity should be in the antibodies. The binding and
stabilization of the tetrahedral intermediate in this case
apparently lowered the energy of activation for the carbonate
hydrolysis. This would subsequently enhance the rate of hydrolysis.
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This is wholly consistent with the notion that an increased










2 WEEKS 2 MONTH
Figure 14. The maturation of antibody affinity as seen in guinea
pigs immunized with 2, 4-dinitrophenyl-BGG. The affinity was
measured by fluorescence quenching with e-DNP-L-lysine . Affinity is
in kcal/mole.
There can be no argument that catalytic polyclonal antibodies
are produced by the immune system of the rabbits, not by the
researchers. We are still presented with the question of whether
the immune system possesses all the required machinery or whether
it evolves its response over the course of an immunization. There
is no doubt that the catalytic activity elicited in this study
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showed a remarkable increase over the course of this study.
Choosing a correct tetrahedral intermediate mimic does have an
effect on the catalytic activity. This will be further probed by
extensive studies in the near future. These results cannot be a
purely genetic phenomenon.
The clonal selection theory seems to be a valid explanation
here. This study does show that over the course of our immunization
we see catalytic activity increase as the amount of hapten specific
antibodies decreases. Therefore, it is probable that as the
immunization proceeds, the antibody producing cells with highest
affinity are selectively stimulated resulting in production of the
higher affinity antibodies. The higher affinity antibodies thus
proliferate later in the response.
The results of this study and our previous variability study,
seem to indicate polyclonal antibodies show a tendency towards a
homogeneous response. The idea that seems to be most logical is a
combination of theories. Do all animals of a species start with a
similar germ line? The high affinity antibodies produced as the
immune response matures probably contain related amino acid
sequences in their binding pockets. The antibody producing cells
all start with a set of restricted germ line variable region genes.
The slight variation seen between unrelated animals may be due to
somatic recombination in the variable region of their genes. If the
56

hapten used is not the best mimic of the tetrahedral intermediate,
the catalysis seen will be less than optimal.
The one piece of data we could not measure directly, due to
time constraints and technical difficulties, was the apparent
affinity or exact composition of the polyclonal antibody response.
There is currently a joint research project being conducted with
the Whitesides' group at Harvard, the goal of which is to show the
distribution of affinities in polyclonal sera. This method will





Polyclonal antibodies have proven to be an effective method
for studying the maturation of a catalytic immune response.
Therefore, polyclonal studies shall also allow complete and
systematic studies of the optimization of hapten and antigen
design. The advantages of this complete, comprehensive, and
resource effective method can no longer be ignored.
The most important trend uncovered here is there is a
tendency towards homogeneity of the catalytic immune response after
repeated immunization. Antibody affinity for the tetrahedral
intermediate is presumed to increase over the immunization regimen.
It is known from previous studies that repeated immunization
results in increased antibody affinity. This increase in antibody
affinity presumably results in an increase in catalysis. Since the
immune system does not purposely evolve to optimize catalytic
activity, the affinity for the tetrahedral intermediate must
incrase over the immunization regimen to see an increase in
catalytic activity. This means the simple binding model of
catalytic antibodies is probably correct. We are assuming that the
increased affinity for hapten stabilizes the transition state to a
greater extent than the ground state, as affinity increases. Thus,
we believe that the higher affinity antibodies that are encouraged
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to dominate the immune response with repeated immunizations are the
best catalysts. These catalytic antibodies may also prove to
contain point mutations which improve catalytic activity. The
actual affinity and affinity distribution of these polyclonal
antibodies shall be measured as soon as an accurate technique
becomes available.
Was Rabbit 2337' s immune response optimized after the third
immunization? The titer had dropped after the fourth immunization.
The rate enhancement and kca t do not change. However, km has
dropped, indicating better substrate binding. The catalytic
efficiency has also increased, thus the only possible explanation
is that there is an increased stabilization of both the substrate
and the tetrahedral intermediate. Rabbit 2337' s immune response is
still optimizing after the fourth immunization!
Let us again emphasize the point that it is not readily
apparent that antibodies should be catalytic. The fact is that
antibodies evolve over the course of the immunization regimen to
bind more tightly to the hapten. The fact that catalysis occurs is
thus an artifact of binding to the tetrahedral intermediate. This
is quite extraordinary. The fact is that the more closely we can
mimic the intermediate of a reaction, the lower the energy barrier
becomes, and the higher the catalytic activity seen.
The rabbits used in this study will continue to be immunized
and studied, to further examine the long term immune response
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maturation. We predict that the immune response will continue to
optimize its catalytic activity through increased affinity. We
should see the affinity for substrate plateau at a relatively low
value, followed by the catalytic activity reaching some constant
value. We do not believe these rabbits have optimized their immune
responses yet, but after several more immunizations, their
antibodies should reach a peak, stable catalytic activity level.
The study will be terminated when the immune response reaches a
stable catalytic level.
Polyclonal antibodies provide us with a unique opportunity to
examine the entire immune response, as opposed to the limited view
presented by monoclonals. Let us go back to our needle in the
haystack analogy. Polyclonals will allow us to first of all ensure
we are searching in the right haystack. They will then allow us to
significantly reduce the magnitude of our haystack, and find the
needle with the sharpest point. Polyclonals will revolutionize the




Materials and Methods. All chemicals were of reagent grade
quality, and purchased commercially. They were used without further
purification.
ELISA readings were conducted on a Bio-Tek Instruments microplate
reader (EL 311) . Analytical HPLC studies were performed on a Hewlett-
Packard 1090M liquid chromatograph with a HP 8452A diode array detection
system and a HP 79994A analytical workstation. H NMR data were obtained
on a General Electric QE-300 MHz instrument.
Preparative low pressure chromatography was done using a HR 10/10
column filled with Gamma Bind Protein G-Sepharose (Pharmacia LKB) using
a Pharmacia LKB fast protein liquid chromatograph (FPLC) , with 2 P-500
pumps, a GP-250 controller, and UV-2 dual path monitor.
Three 5 pound heterozygous male New Zealand white rabbits were
obtained from R&R Rabbitry, Pipe Creek, Texas.
The reaction buffer used in all studies was 10 mM Tris buffer.
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Preparation of Protein Conjugates. Hapten (12.0 mg, 0.0216
ramol) and KLH (20.0 mg) were placed in 2.0 mL lxPBS; N-
hydroxysulfosuccinimide (8 mg, 0.0369 mmol) and [l-ethyl-3-
(dimethylamino) propyl] -carbodiimide (12mg, 0.0625 mmol) were added. The
mixture was stirred for 60 min at room temperature. The conjugate was
dialyzed against lxPBS buffer (3x) for 3 days. This solution was diluted
to 1 mg/mL (protein concentration, and stored at -20 C. The same
conjugate was used to prepare ELISA plates.
Rabbit Immunizations. Three 5 pound male New Zealand rabbits
were bled as a control. A mixture of 0.5 ml hapten-KLH (1 mg/mL) and 0.5
mL Freund' s complete adjuvant was prepared. Seven days later each of the
3 rabbits was subcutaneously injected with a 1 ml mixture on the dorsal
surface between the shoulders. The injection was administered in 3 to 4
different spots. Subsequent injections used Freund' s incomplete
adjuvant. The rabbits were immunized at 21 day intervals. Bleeds of
about 10 mL were conducted 10 days following each injection.
Antibody Isolation and Purification. The whole blood was
immediately separated into cells and serum by centrifugation at 10,000
g for 10 min. The serum was separated and stored overnight at -20 C,
and the cells were discarded. The serum was thawed. Two volumes of 60 mM
sodium acetate, pH 4.0, was slowly added to the serum while stirring.
The pH was adjusted to 4.8. While continuing to stir, 0.75 mL caprylic
acid per 10 ml of serum was added dropwise. The mixture was shaken for
an additional 30 minutes. The solution was then centrifuged at 5000 g
for 10 min. The supernatant was decanted and placed in 50,000 molecular
weight cut-off tubing (MWCO) , and dialyzed overnight against three
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changes of 10 mM Tris, at 4 °C. The dialyzed samples were then mixed
with an equal volume of saturated ammonium sulfate while slowly
stirring. The solution was then allowed to stand at 4 C overnight
(£.6 h) . The mixture was then centrifuged at 3000 g for 30 minutes. The
supernatant was decanted and discarded. The white pellet was suspended
in 0.3 to 0.5 volumes of Tris buffer. The dissolved pellet was then
loaded into 50,000 MWCO dialysis tubing and dialyzed overnight, at 4 C,
against 3 changes of Tris buffer. The solution was centrifuged at 3000
g for 10 min to remove any debris. The samples were then purified on a
HR 10/10 column filled with Protein G-Sepharose 4 Fast Flow using an
FPLC system with ImmunoPure Binding and Elution buffers. The purified
samples were neutralized with Tris buffer. The samples were then
concentrated by ultrafiltration. The samples were again dialyzed, in
50,000 MWCO tubing, against 3 changes of Tris buffer overnight, at 4
C. The concentrations of purified IgG were determined by absorbance at
280 nm. The purified samples were kept at -20 C when not in use.
Preparation of ELISA Plates. The hapten-KLH conjugate was
diluted 1:500 in Tris buffer, and 25 mL added to each well of a 96 well
low affinity ELISA plate. The plate was then placed at 37 °C overnight.
ELISA-Titer Determination. The hapten-KLH was fixed onto the
plate by placing 50 J1L of methanol into each well and allowing to stand
10 min. The methanol was removed and the plate air dried. To each well,
was added 50 |1L of a BSA solution (1 mg/mL) in Tris. The plate was
stored in a moist chamber at 37 °C for 1 h. The BSA solution is removed
and 25 \lh of the same BSA solution is added to each well except those in
the first column. To the first well in each row, is added 50 |IL of a
solution of 1:100 antibody sample. The antibody sample was then serially
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diluted by taking 25 p.L from the first row and transferring it to the
next well and mixing thoroughly. This procedure was repeated across each
row from well 1 to 12. The plate was then stored in a moist chamber at
37°C for 4 hours. The plate was then rinsed 10 times in a stream of
water. A secondary antigen of Goat-anti rabbit was diluted 1:500 and
25JJ.1 added to each well. The plate was placed in a moist chamber at 37
°C for 1 hour. The plate was rinsed 10 times in a stream of water. To
each well was then added 50 \LL ABTS . The plates were read at 5 and 15
minutes. The readings were then averaged.
Catalytic Assays. The catalytic assays were carried out in 20
JJ.L volume reactions. The reactions contained 18 |!L of a premixed
antibody solution, and 2 (J.L of a substrate solution. The antibody and
substrate solution were diluted with 10 mM Tris buffer as necessary.
Substrate concentration in the reactions varied from 30 to 150 |iM. The
background hydrolysis rate was determined in the absence of antibody.
The reactions were incubated at 25 C for 1 to 7 h, and then immediately
analyzed by HPLC. All reactions were run for 10-30 % product conversion
and were repeated in triplicate. Lineweaver-Burk analysis was done to
determine vmax and km . The standard deviation was determined by plotting
the three sets of data separately for each rabbit and bleed. Standard
deviations calculated using the following equation.
S = [S(Xi -xave )
2 /N-l]° 5
The reported Lineweaver-Burk data is that extracted from the plots of
the average of three data points. The error in the integration of peaks
is ±5 %.
HPLC Analysis. The samples were injected onto a 4.6 mm X 15 cm
Vydak Cis column with a Vydak C]_8~fill ec* precolumn. The elution
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conditions consisted of a flow rate of 0.7 mL/min of 40 % methanol /60 %
ddH20 for 6.0 min, followed by a 0.2 min ramp up to 70 % methanol,
after 3 min, a 0.20 min ramp down to 40 % methanol. The reaction
products consisting of the phenol and the 4- (butylamide) benzyl alcohol
eluted at about 5 and 6 min respectively. The starting substrate eluted
off at about 11.7 min. Products were identified by coinjection with
known compounds. Reaction rates were determined by peak integration. The
conversion to product was determined by integrating the product peak at
~ 6.0 min, and dividing by the sum of the integration of itself and the
substrate peak at ~ 11.5 min. The integrations were done at 235 nra. The
phenol peak existence was verified at 210 nm.
Background Rate Determination. The background rate was
determined in reaction buffer, and in reaction buffer in the presence of
prebleed serum. A solution of 150)lm substrate was allowed to stand for 2
days at 25 C. The reaction mixture was analyzed for conversion of
substrate to product by HPLC.
The background was also determined in the presence of prebleed
sera. The reactions consisted of 16-19 ]1M antibody from the prebleed,
and 150 |1M substrate. The reactions were allowed to go for 2 days. The
reactions were analyzed by HPLC.
Background rates were determined from the following equation:
Background Rate = kunca t = {- In [s] f/ [s] i } /time (min)
Prebleed Serum Activity. To verify the lack of catalytic
activity present prior to immunization, catalytic assays using prebleed
serum were conducted. The reaction volumes were 20 |IL. The reaction
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consisted of 150 \lM substrate and 16-19 |IM serum. A second set of
reactions included 16-19 |1M inhibitor. The reactions were incubated for
8 to 9 h at 25 °C. The reactions were then analyzed by HPLC.
Inhibition Analysis: Reaction solutions were each 20JJ.L. They
consisted of 16 p.L of antibody solution, and 2 p.L of a hapten solution
of varying concentrations. The hapten concentration was varied from to
20 % of the antibody binding site concentration. The antibodies were
incubated with the hapten for at least 18 min. Then 2|iL of substrate was
added to bring the substrate concentration to 150 }1M. After 18 min at
25 C, the reaction were analyzed by HPLC. All reactions were run for
10-20 % product conversion. The results for each individual sample were
plotted as fraction of substrate converted versus percentage of hapten.
A straight line was drawn through the points. The point where the line
intercepts the x axis is considered the percentage of active antibodies.
Determination of Theoretical Inhibition Plots. The math program
Mathematics Version 2.2 (Wolfram Research) was utilized for this
analysis. The program was allowed to solve a series of five equations,
with five unknowns, for a general solution. The solution would be for
the concentration of antibody bound substrate, or Ab-S. Known values
were inserted for the antibody concentration, the substrate
concentration, and km and the program was then allowed to come up with
a simplified equation for Ab-S. Then the equation was solved for values
of kft. The values used for kh were 0.00001, 0.0001, 0.001, 0.01, 0.1,
0.99, 10.0, and 100.0. Into each equation obtained for various values of
kh were plugged values for hapten from 0.0 to 30.0 mM. The values
obtained for Ab-S were normalized and plotted against normalized values
of hapten. The eight curves (one for each value of kh) were compared to
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an actual normalized inhibition plot to validate the characteristics of
the curve seen, and get an estimate of the actual k^.
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B: Research Objectives and Aims
The research described in this thesis gives us a better
understanding of the molecular recognition properties of the
sapphyrin-type expanded porphyrin. It has been discovered in our
labs that the sapphyrins have the ability to selectively recognize
and bind anions (94-98 ) . By attaching sapphyrin molecules to a
chromatographic support, one can further probe the interactions
between various anions and the sapphyrin. This work shows the
feasibility of using expanded porphyrins, specifically the
sapphyrin class, as a chromatographic support for analyzing and
purifying mixtures of anions, such as phosphates. This study
focuses on the development of a sapphyrin-modified silica support
for use in HPLC analysis.
The ability of sapphyrins to bind DNA through phosphate
chelation led us to realize that a sapphyrin-bound silica gel could
be used to separate oligonucleotides as well as DNA and RNA
fragments. Sapphyrin binds to DNA with a high affinity, showing a
K a of 2.5 x 10 M" (99) . This could provide a tool for use in
purification of synthetic oligonucleotides, and nucleic acids. The
ability of sapphyrin-based chromatographic supports to recognize
and bind other anions of interest will also be investigated.
In a less successful project, a sapphyrin dimer was proposed
in order to enhance our understanding of the interaction of
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sapphyrin and DNA in solution. Since it has been proven that
sapphyrin is able to bind double stranded DNA (99) in solution. It
would be interesting to find out whether a conjugate with two
sapphyrins will show enhanced binding to DNA.
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B: Background and Significance
Sapphyrin. Sapphyrin 1 is a pentapyrrolic expanded
macrocycle, which belongs to a group of molecules referred to as
expanded porhyrins 2 (100) . It was first reported by Woodward and
coworkers (101,102), who discovered it while attempting to
synthesize vitamin B-12.
1 2
Figure 15. The basic structure of sapphyrin and porphyrin.
The sapphyrin macrocycle is monoprotonated at neutral pH
(99). Thus, the interior of the sapphyrin macrocycle forms a large
basic cavity (95,103,104). The four protons present in the
monoprotonated core are capable of forming strong hydrogen bonds to
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select anions such as fluorides and phosphates, in both solution
and solid state (105,106).
Sapphyrins have been shown to possess unique molecular
recognition properties towards certain anions (94-96,103-109). Due
to the nature of these reactions, they represent the chelation of
the anions by the protonated core. A crystal structure of the
diprotonated form of sapphyrin showed it chelating a phosphate
anion, see Figure 16 (96)
.
Figure 16. Representation of the X-ray crystallographic structure
of the 1:1 complex formed between the monoprotonated sapphyrin
macrocycle and phosphoric acid.
The ability of sapphyrin to chelate to the phosphate backbone
presented a unique DNA-small molecule interaction that was
discovered by Shreder of our group (99) . The initial evidence for
this interaction was the result of mixing an excess of water
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soluble sapphyrin 1, which in solution is a deep emerald green
color, to double stranded DNA at neutral pH. The result was an
immediate precipitation of green fibers. The results of solid state
31
P NMR analyses further support this event as being a chelation
interaction (110)
.
UV-Visible studies were used to calculate an apparent binding
constant of 2.5 x 10 4 M" 1 for sapphyrin to single stranded DNA (99).
The results seen for the case of sapphyrin to double stranded DNA
yielded similar spectral shifts, but the calculations were more
complex. The spectral shifts could be the result of more than one
interaction in solution. The sapphyrin, which is known to aggregate
in solution, may be aggregating at high sapphyrin to DNA
concentrations
.
The possibility that sapphyrin was intercalating was ruled
out by studies with Topoisomerase I (111). In the presence of
sapphyrin, dsDNA was not unwound by Topoisomerase I. This indicates
that intercalation was not the mode of interaction. Thus, this type
of interaction is referred to as phosphate chelation.
Modified Solid-Supports. Cram (112) and others (113-118)
have demonstrated that the attachment of a molecule to a solid
support may yield insights into the nature of the receptor (solid
support attached) -substrate interactions. This approach allows
binding interactions involving a large number of substrates to be
rapidly analyzed, under identical experimental conditions. Thus,
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receptor molecules can be quickly evaluated to determine their
potential for use in new or improved chromatographic supports.
Chromatographic methods can be designed to exploit specific
receptor-substrate interactions. The result is the ability to
define subpopulations of molecules (119) . This idea of using a
receptor ligand covalently attached to a solid support is sometimes
referred to as affinity chromatography. In HPLC applications, this
is called High Performance Affinity Chromatography (HPAC) (120)
.
The macrocyclic polyethers known as crown ethers have shown
the ability to form complexes with cations (121) . There are many
examples of functionalized crown ethers being covalently attached
to solid supports for use in ion chromatography (115)
.
As an example, Cram reported that a crown ether receptor
molecule covalently attached to a solid support was able to
optically resolve amino acids and ester salts (112) . In this case,
a large optically active crown ether was covalently attached to
cross-linked polystyrene-divinylbenzene resin. The resultant resin








Figure 17. Solid support synthesized by Cram for optical
resolution of amino acids and peptides.
The practice of preparing silica-bound macrocycles has been
greatly expanded by the works of Bradshaw and Izatt (113,114,122).
Silica-bound aza-crown and poly-aza crown macrocycles were used to
probe crown molecule selectivity towards metal ions. The stable
silica-bound macrocycles were able to be used in multiple studies,
while preserving the precious macrocycles. It was also discovered
the bound macrocycles showed selectivities and binding properties
similar to those seen in the unbound macrocycles.
Schilde and Uhlemann reported the use of a special chelating
type resin for separating oxyanions (123) . The chelating resin was
produced by the reaction of chloromethylated styrene-divinylbenzene
polymer with an amino sugar, 1-deoxy-l- (methylamino) -glucitol
groups (Figure 18) . The two hydroxyl groups in the cis position
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were able to form certain oxyanion diol complexes. Selective
separation of aluminate, gallate, germinate, plumbate, vanadate,
and molybdate from brines were seen.
OH
I OH OH OH
CH3
Figure 18. Methylamino-glucitol groups of the special chelating
resin.
There are many examples of metal-porphyrin complexes being
incorporated into solid supports (124). Kokufuta et al . reported
the use of chloromolybdenum (V) tet raphenylporphyrin complex
containing polymer as an anion exchanger (118). The solid supports
were then submersed in a solution containing phosphate ions. The
concentration of anions in solution was measured. The porphyrin
complex showed a slight preference for the phosphate anion over the
chloride anion.
Meyerhoff and coworkers have done extensive investigation
into the anion selectivity of various types of porphyrin complex-
modified solid supports (117). They prepared and characterized
covalently bound porphyrin-silica gel stationary phases, with
tetraphenyl porphyrin covalently attached to silica gel. The
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porphyrin was subsequently metalated with either tin (IV) or indium
(III) . By varying the metal in the core of the porphyrin, the
selectivity of the modified-silica gel was modified for aromatic
anions. This indicates the metal in the macrocycle is capable of
coordinating with anions in solution.
Meyerhoff and coworkers have also investigated the anion
selectivity of potentiomet ric response of poly (tetrakis (p-
aminophenyl) porphyrin) film-modified electrodes (116), the
thiocyanate selectivity of Mn ( II) -porphyrin-based electrodes
(124), and the potentiomet ric anion selectivity of polymer
membranes doped with Indium (III) -porphyrins (125).
Separation of Biologically Relevant Molecules. HPLC
and other solid supported chromatography methods are finding
increased usage in the separation, purification, and analysis of
phosphorylated species such as nucleotides, oligonucleotides, DNA
and RNA fragments, anti-viral treatments, pharmaceuticals,
environmental contaminants, and chemical warfare agents.
A variety of new separation techniques, as well as
modifications of existing techniques, have been recently developed
(126). Many of these techniques prove to be expensive and quite
often inefficient. Efficiency is a paramount concern, as the
separation of compounds in pharmaceutical and certain biotechnology
industries must show greater than 99.9 % purity (sometimes > 99.99




Natural sciences have turned to HPLC as a preferred method
for the separation and analysis of biological molecules. There
have been many reports detailing the use of HPLC (127-132) . They
include the use of silica phases with bonded groups, such as linear
hydrocarbons, amino and cyano-groups, carboxylic amides, amino
acids, etc. (127-132). Researchers still commonly use radio-
labeling and gel electrophoresis (GE) in cellular and synthetic
oligonucleotide purification and analysis. The methods of GE and
radio-labeling can be relatively time-consuming, painfully manpower
intensive, and low yielding (133,134). Thus, an improved method for
separating these types of molecules would have significant value.
The importance of being able to efficiently purify synthetic
oligonucleotides is obvious. Synthetic oligonucleotides have a
broad range of applications in biotechnology. The applications
include providing templates for carrying out deletions, additions,
and site specific mutagenesis, acting as adapters for cloning, and
performing construction of genes. In the areas of interest that are
currently being monitored by the US Food and Drug Administration
(FDA) , are probes for the detection of genetic diseases, probes for
the detection of the provirus of Acquired Immunodeficiency Syndrome
(AIDS) , cloning techniques used for the treatment and diagnosis of
infectious diseases, and purification and analysis of modified




Takemoto et al. recently proposed an alternate separation
technique. It employed bonding purine and pyrimidine bases on the
surface of silica gel (136) . This approach improved separation of
nucleic acids by base pairing interactions with their silica-bound
nucleic acid base pairs. Takemoto et al . showed such stationary
phases could be used to separate nucleic acid free bases, purine
alkaloids, nucleosides, nucleotides, and oligonucleotides.
Separation of nucleotide mono-, di-, and triphosphates from
cell extracts have often been problematic. The ability to separate
the adenylate mono-, di-, and triphosphates is in itself
instrumental in determining cell energy charge. The cell energy
charge is given by:
Adenylate Energy Charge = { [ATP] +0 . 5 [ADP] } / { [AMP] + [ADP] + [ATP]
}
The energy charge is used as a determination of cell health in the
study of many diseases (137,138).
Ion exchange HPLC columns for separating nucleotides and
oligonucleotides already exist. Some of these columns utilize a
bonded silica phase that operates by a weak anion exchange
principle, and provides modest separations of nucleotides of up to
30 residues and other small molecules. There are several different
bonded silica phase HPLC columns available that utilize a strong
anion exchange principle to provide limited separation of
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nucleotide monophosphates. There are also several utilizing a
strong cation exchange interaction to separate nucleic acid bases.
In the area of synthetic oligonucleotide separations, there are
HPLC columns available that can on a limited basis separate
oligonucleotides of 40 residues or less. Many of these columns are
severely limited in their range of applications or in some cases
require harsh conditions. For example, Diethylaminoethyl (DEAE)
systems are able to achieve separations of nucleotides and
oligonucleotides with good purity, but require a pH as low as
2.0(139) .
The main disadvantages in using HPLC are lengthy analysis
times and a lack of high efficiency in the analytical mode (140).
There are also often inadequate yields in preparatory modes. The
use of high-performance capillary electrophoresis (HPCE) shows
promise in analytical modes. HPCE is one of the most significant
bioseparation tools developed in the past twenty years. It is a
highly sensitive analytical method capable of providing the rapid
and efficient separation of a variety of species from complex
mixtures 141) . HPCE has shown promise in the analysis of
pharmaceuticals, amino acids, proteins, nucleotides and DNA. The
work of Zare et al . has shown great promise in the analysis of cell
profiles of human peripheral blood lymphocytes and Molt4 human
leukemia cells in the study of intracellular metabolism of
nucleotides relating to the understanding of AIDS (138) . The main
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disadvantage of HPCE is that it is limited to small scale
analytical separations.
A focus of research in our labs is the synthesis and study of
expanded porphyrins (100,106,142). It was found the sapphyrin
macrocycle exhibits unique molecular recognition properties towards
anions (143) . Recent attention has focused on the binding of
biologically important phosphate species. Nucleobase substituted
sapphyrins showed selective transport of monophosphates at
physiological pH. The interaction of sapphyrin with DNA, which we
have termed phosphate chelation, displays a mode of binding not
previously seen in porphyrin chemistry (99). This presents the
possibility of practical medical and biotechnological applications
(96) .
Environmental Concerns. Environmental concerns are
taking center stage in all of our lives. Chromatography proves to
be one of the most important methods for analyzing for pesticides,
herbicides, fungicides, and their primary hydrolysis products (144-
148). Many pesticides contain organophosphorous compounds.
Organophosphorous compounds are known to inhibit
acetylcholinesterase in mammals (149). It would be significant to
develop better methods to analyze ground water, soil, food stuffs,
etc., for contaminants such as the pesticides Dichlorovos,
Phosphamidon, Diazanon, and Parathion.
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Chemical Weapons. The end of the Cold War has left the
United States and the former Soviet Union with large stockpiles of
chemical warfare agents. Third World nations such as Libya and Iran
are turning to this relatively low technology, but extremely
devastating weapons of mass destruction. Some of these chemical
warfare agents, such as Sarin, and their primary hydrolysis
products are organophosphorous compounds. The magnitude these
problems are self-evident (150-152)
.
Our sapphyrin-substituted silica gels may allow for detection
and analysis of these noxious agents, and their primary hydrolysis
products. This, in turn, would allow one to deal with disposal in
those cases where they are present.
Sapphyrin Dimer. A second, different sapphyrin project was
also carried out. It has been shown that sapphyrin binds to double
stranded DNA in solution (99) . We are interested in seeing if a
second covalently attached sapphyrin would greatly increase the
affinity for double stranded DNA. It has proven difficult to
spectroscopically show the binding constant of sapphyrin to dsDNA,
therefore an Fe (II)-EDTA type entity will be covalently attached
to the sapphyrin dimer to effect cleavage of the DNA. Fe (II)-EDTA
is known to cleave DNA (153,154), and thus we will be able to
compare the effect of a second covalently attached sapphyrin on an




Overall Significance. The most significant goal of this
research is to demonstrate the feasibility of using solid supported




Synthesis of the Sapphyrin-modifled Silica Gels. The
sapphyrin modified gels were synthesized by an amide coupling, as
shown in Figure 19. These synthesis were performed by Krai in our




















Figure 19. Synthesis of sapphyrin-modified silica gel
83

Effect of PH Variation on AMP Retention on SG-1.
Under isochratic HPLC conditions of 0.2 mL/Min flow, using 100 mM
ammonium phosphate (dibasic) , the pH of the buffer was varied to
investigate the effect on retention of 5' -AMP on the 4.6 mm x 10 cm
SG-1 column. The pH was varied from 5.6 to 8.0. In this pH range,
the sapphyrin is monoprotonated. The results are shown in table 12.
The results showed the shortest retention time for AMP to be at pH
7.0.




Table 12. Retention times for 5' -AMP at varying pH.
Nucleotide Retention on SG-1. The retention of various
monophosphates, as well as the mono- to triphosphates of adenosine
were checked at pH 7.0 on the SG-1 column. Isochratic HPLC
conditions of 0.10 mL/min and 100 mM ammonium phosphate were used.
The results are shown in Table 13. The results clearly show the
retention time increases with the number of phosphates present. The
results also show a remarkable preference for the 5' -adenosine









Adenosine 23.2 23.2 (11.4)*











Table 13. Retention times for nucleotides. *Indicates run at 0.20
mL/min.
Retention of Polydeoxyadenylic Acids on SG-1. The 3-
through 5-mers of polydeoxyadenylic acid were checked for
variations in retention time versus the number of phosphates.
Isochratic HPLC conditions of 0.20 mL/min flow and 100 mM ammonium






P(dA) a 220.0 63.7
P(dA) s 460.0 123.0
p(dA)
fi 820.0 289.0
Table 14. Retention times of the p(dA) 3 . s series.
Retention Times of Various Anions on SG-2 and
Control Column. Various anions were injected onto SG-2 under
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isochratic conditions of 0.2 mL/min and 100 mM ammonium phosphate.
The anions were also injected onto the control column under under
the same isochratic conditions to check for retention times. The
results are shown in Table 15.










Benzophenone 6 6.8 6.4
Benzenesulfonic
Acid
2.55 6 -1 5.9 8.3
Benzoic Acid 4.20 6 -1 5.0 10.4
Phenylphosphinic
Acid
2.10 6 -1 5.8 10.7
Phenylphosphonic
Acid
1.83 7.07 6 -1 5.9 12.0
Phenylacetic Acid 4.31 6 -1 5.7 12.9
Diphenylacetic
Acid
3.94 6 -1 8.2 14.3
Phenylarsonic Acid 4.53 9.52 6 -1 6.1 16.0
Diphenylphosphoric
Acid
1.85 6 -1 5.9 20.5
Homopthalic Acid 2.95 5.41 7 -2 5.7 9.9
Benzylphosphonic
Acid
2.38 5.98 7 -2 6.0 14.6
Phenylphosphoric
Acid
1.48 5.70 7 -2 5.6 15.3
Table 15. Retention times for various anions (±0.2 min).
Retention Times for Nucleotides on SG-2 . The adenosine
series of nucleotides were injected under various isochratic
conditions of 0.20 to 1.0 mL/min and 0.5 to 1.0 mM ammonium


















0.5 M & 0.8
mL/min
Adenosine 2.6 7.5 1.3 1.7
5 '-AMP 5.0 12.5 2.7 3.4
5'-ADP 6.3 14.8 3.9 4.9
5'
-ATP 7.5 17.5 5.6 6.9
Table 16. Retention times of the adenosine series on SG-2.
Retention Times of P(dA) 2 . 9 on SG-2. The retention times
of the p(dA) 2 . 9 series were determined under isochratic HPLC
conditions of 1.0 mL/min and 1.0 M ammonium phospahte. It was found
















Table 17. Retention times of p(dA)2-9. Average of 2 runs, error
of ± 0.2 min.
Retention Times of P(dC)-p(dA) Mixes on SG-2. The
p(dC)-p(dA) retention times were determined under isochratic HPLC
conditions of 0.10 mL/min of 0.5 M ammonium phosphate. It was





p(dA) 3,p(dA) 4 ,p(dA) 5 ,p
(dA>,
Retention Time (min)
p(dC) 3 ,p(dA) 4 ,p(dC) 5 ,p
(dA)
fi
p(dA), or p(dC), 27.6 20.2
p(dA), 38.0 36.6




Table 18. Retention times of p(dA)-p(dA) mixes.
Retention Times on DEAE Columns. The various anionic
species injected on the sapphyrin-silica gels were injected onto a
commercial DEAE column at neutral pH to check, for anion
selectivity. Isochratic HPLC conditions of 0.4 mL/min and 0.5 mM
ammonium phosphate were used. The results are shown in Table 19.
















Table 19. Anion retention times on DEAE column.
Column Efficiency of SG-2 . The column efficiency, or
number of theoretical plates, was determined by eluting benzene
under isochratic conditions of methanol/water (50/50) and 0.1
mL/min flow. The efficiency was determined from the average of four
runs. The results are given in Table 20.
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Run t r (min) t w (min) N
1 7.4 1.6 327
2 8.1 1.2 846
3 7.9 1.2 628
4 8.1 1.4 535
Average 7.9 1.4 584
Table 20. Determination of column efficiency.
Stationary Phase Coverage. The stationary phase coverage
was determined by the method of Unger (156) . It relies on the









480 4.85 1.62 2.58
Silyl-
ated
480 5.57 1.45 0.66
SG-2 480 7.32 1.85 0.124
Table 21. Stationary phase coverage.
Energetics of Binding. The change in Gibbs Free Energy
per phosphate can be determined by the method outlined in the
Methods section. The graphs of retention time versus number of
phosphates and change in free energy per phosphate are shown in
Figures 20-23 as well as representative HPLC chromatographs . The
results are shown below for the p (dA) 2 . 9 case
.
Plotting the change in free energy versus the number of
phosphates shows free energy values of 233, 200, and 270 cal/mol

















































25.0 35.05.0 10.0 30.0
Figure 21. Chromatogram of adenosine,
separation under isochratic conditions.
AMP, ADP, and ATP
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RETENTION TIME v. IPHOSPHATES FOR POLY A (2-»)
4 <
I PHOSPHATES










-t «."»• • 0-31 W/i H. 0»mj
3 4 5
I PHOSPHATES
Figure 22. Changes in retention times (a.), and free energy (b. )
,
per phosphate for the p(dA)2-9 series.
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Figure 23. Changes in retention times (a.), and free energy (b.),
per phosphate for the adenylate series.
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3 2.1 1.235 0.334
4 3.4 2.000 0.6195 284.9
5 5.7 3.350 0.597 304.5
6 8.8 5.180 0.647 257.3
7 13.5 8.06 0.643 261.1
8 19.5 11.47 0.703 208.0
9 29.3 17.24 0.665 240.5
Table 22. Free energy per phosphate for the p(dA) series.




AMP 2.4 1.42 0.25 818
ADP 3.8 2.23 0.63 272
ATP 5.8 3.41 0.654 251
Table 23. Free energy per phosphate for adenosine series.
Sapphyrin Dimer-EDTA Conjugate. The sapphyrin dimer EDTA
conjugate was synthesized several times by the method shown in
figure 24. The synthesis consisted of a modular construction of the
molecule using a series of amide couplings. The major problem
associated with this molecule is solubility, of rather a lack of
solubility in solvents. The sapphyrin dimer and the sapphyrin
dimer-EDTA conjugate could not be characterized by proton NMR in
any of a variety of deuterated solvents. Proton NMRs were attempted
in deuterated versions of chloroform, dichloromethane
,
dimethylsulfoxide, methanol, benzene, and pyridine. These NMRs
could not be interpreted due to problems with solubility and







1. CH2CI2t Oxalyl Chloride





CH2CI2 , Pyridine, Argon, 24 h
5. TFA, CHgClg, Argon, 30 min
1. THF, Carbonyl diimidizole, Argon, 1 h





Figure 24. Synthesis of sapphyrin dimer-EDTA conjugate
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Several attempts were made to deprotect. Deprotection was finally
accomplished, but the conjugate proved difficult to characterize.
The sapphyrin dimer-EDTA conjugate seemed to readily complex copper
from the mass spectra probe. It was shown by low resolution mass
spectra that an iron molecule could be complexed, but high
resolution mass spectra could not be obtained.
Supercoiled Assay. Figure 25 shows the results of the
supercoiled assay. The sapphyrin dimer-EDTA conjugate did not
appear to show any higher activity than Fe-EDTA at the same
concentration
.
Figure 25. Supercoiled assay. Each lane contains 7 fiL of pipes (5
mM), 0.6 (XL ofsupercoiled DNA, and 1 HL of DTT (lOmM). Lanes in
order of left to right, 1. DNA only, 2. 10 |IM sapphyrin dimer, 3. 5
|iM dimer, 4. 2.5 [1M dimer, 5. 1.25 (IM dimer, 6. . 67 |1M dimer, 7.
10 {IM FeEDTA, 8 . 5 |IM FeEDTA, 9. 2 . 5 |IM FeEDTA, 10. 1.25 (IM FeEDTA,
11. 0.67 JIM FeEDTA. The bands are from top to bottom, nicked
supercoiled DNA, and supercoiled.
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Calf Thymus DNA Titration. The titration of 6 mM of the
sapphyrin dimer-EDTA conjugate showed no spectral shifts. The
absorption spectra indicated that the conjugate was in a state of
aggregation, even with 10% Tween or SDS. As, calf thymus DNA was
titrated in there was no significant change in the spectra. The
amount of calf thymus added was from 1 to 100 equivalents of DNA
phosphates. The sapphyrin monomer-EDTA conjugate showed an llnm
bathochromic shift of its singular Soret band. The results seen for
the dimer are shown in table 24. These results indicate there was
no binding interaction seen between the dimer conjugate and the
calf thymus DNA.











Sapphyrin-Modified Silica Gel. The sapphyrin-modified
silica gel shows selectivity for certain anionic species under
isochratic HPLC conditions. The results do not appear to represent
a purely Tt-stacking or hydrophobic event. The benzophenone or
benzene species, which are neutral, are not retained to any great
extent. We however see that various monoanionic and polyanionic
species are retained to differing extents. These results can be
compared with those seen in the case of the DEAE column. The DEAE
column does interact with anions through some hydrophobic weak,
anion exchange principles. We can see a marked difference in the
order of retentions under neutral, isochratic HPLC conditions.
There is also strong evidence that the interaction seen is
not the result of pure electrostatics. There is a wide range of
retention times for monoanionic species. For example,
benzenesulfonic acid is retained for 8.3 minutes, while
diphenylphosphoric acid is retained for 20.5 minutes under the same
conditions. The homopthalic acid, which is dianionic, is retained
for only 9.9 minutes. Thus, the results seen cannot be a totally
electrostatic phenomenon. The interaction appears to be the result
of the phosphate chelation interaction proposed.
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There appears to be a correlation between the accessibility
of the oxyanion and the anion selectivity. The central atom-to-
oxygen distances for benzenesulfonate, phenylphosphonate, and
phenylarsonate are 1.47, 1.52, and 1.69 A respectively (155). If we
accept the idea of phosphate chelation being the mode of
interaction, we would predict that longer central atom-to-oxygen
bonds would result in longer retention times. This is exactly what
is seen.
The fact that oligonucleotides are retained according to the
number of phosphates present is expected. In calculating the free
energy change per phosphate we see that the effect of each
additional phosphate group is additive. This again is consistent
with phosphate chelation.
Sapphyrin Dimer-EDTA Conjugate. The sapphyrin dimer-EDTA
conjugate proved difficult to characterize. It appeared to be
aggregated under aqueous conditions. Combined with the low
solubility, this is presumed to have prevented the conjugate from
binding to the DNA phosphates. This sapphyrin dimer-EDTA conjugate
was not pursued further due to the lack of activity with
supercoiled DNA and calf thymus DNA.
It is possible to imagine improving the solubility of
sapphyrin dimers by adding water solubilizing molecules such as
sugars. There is also the possibility of using a more rigid linker
to prevent the intramolecular interaction from preventing
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interaction with DNA phosphates. The most probable success would





Sapphyrin-modified Silica Gels. The sapphyrin-modified
silica gels provide a valuable insight into the anion selectivity
of sapphyrin. The nature of the this sapphyrin-anion interaction
appears to be based on the accessibility of the oxyanion for
chelation to the basic sapphyrin core. This allows us to accurately
predict the selectivity of sapphyrin for various anions in
solution.
The sapphyrin-silica gels also proved to be capable of
efficient separation of oligonucleotides and nucleotides. Thus, the
process of attaching macrocycles to solid supports can be expanded
to studying the binding properties of other expanded porphyrin
macrocycles. One sees that in probing the interaction of receptor-
substrate interactions, feasible applications of these receptor-
modified supports may be realized.
Sapphyrin-Dimer . The sapphyrin dimer-EDTA conjugate proved
to be ineffective in interacting with DNA. The fact that this
molecule does not interact with DNA led us to discontinue work with
this particular molecule. There are several other people in this
group who are synthesizing sapphyrin dimers with different linkers




Materials and Methods. Solvents and reagents were
purchased commercially. They were of reagent quality and used
without further purification, unless otherwise noted.
1
H and x C NMR spectra were measured on a Bruker AC 250 MHz
instrument or GE 300Mhz instrument and are reported in parts per
million (ppm) of tet ramethylsilane . Elemental analyses were
performed by Atlantic Microlab, Inc. Fast atom bombardment (FAB)
mass spectra were performed by the University of Texas Mass
Spectral Facility at Austin, Texas.
Low pressure liquid chromatography was performed using a
PrepRPC 15 mM reverse phase column using a Pharmacia LKB fast
protein liquid chromatograph (FPLC) , with 2 P-500 pumps, a GP-250
controller, and UV-2 dual path monitor. Analytical HPLC was
performed using either a Hewlett-Packard 1090M liquid chromatograph
with a 8452A diode array detector, or a Varian LC Star 9002 Solvent
Delivery System with a Varian LC Star 9050 UV-Vis Detector.
The aminopropyl silica gel (Aldrich) used to prepare the
sapphyrin-silica gel columns consisted of spherical particles with
a mean diameter of 52 mm, a pore diameter of 60 A, a pore volume of
0.75 cm /kg, and a surface area of 480 m /g. HPLC analytical




Effect of Varying pH on Retention of AMP on Column
SG-1. Adenosine 5' -monophosphate (5 mM) was injected onto the
Hewlett Packard HPLC in 10ml amounts. The pH of the buffer (100 mM
(NH 4 ) 2HP0 4 ) was adjusted to 5.6, 7.0, and 8.0. Isochratic HPLC
conditions with a flow of 0.2 mL/min were used. Differences in
retention times were determined by monitoring 2 60 nm.
Determination of Retention Times for Nucleotides on
SG-1. Solutions of 5' -AMP, 5' -CMP, 5'-GMP, and 5'-UMP (5 mM) were
prepared. The solutions were injected (20 mL) singularly and in
mixtures. Isochratic HPLC conditions of 0.10 mL/min of 100 mM
(NH 4 ) 2HP04 were used. Data was recorded at 260 nm. The mono- to tri-
phosphates of adenosine were repeated at 0.20 mL/min.
Determination of Retention Times for
Polydeoxyadenylic Acid [p (dA) ] on SG-1. Solutions of p(dA) 3 . 6
were prepared as follows. Five units of the p(dA) were dissolved in
pipes buffer (5 mM, pH 7.0). The solutions were injected (20 mL) as
a mixture. Isochratic HPLC conditions of 0.20 mL/min of 100 mM
(NH 4 ) 2HP0 4 and pH 7.0 were used. Data was recorded at 260 nm. The
run was repeated at 0.35 mL/min.
Determination of Retention Times for Various Anions
on SG-1. Solutions of various anions in H 2 were prepared. For
each anion, 15 mL were injected under isochratic conditions with
(NH 4 ) 2HP0 4 (lOOmM) at pH 6.0 or pH 7.0 and a flow rate of 0.2
mL/min. Runs were monitored at 210 and 260 nm.
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Retention Times on Control Column. The previous
procedures were repeated using the silyl-capped control column (no
sapphyrin)
.
Determination of Retention Times for Nucleotides on
SG-2. Solutions of adenosine, 5' -AMP, 5'-ADP, and 5' -ATP (5 mM)
were prepared. The solutions were injected (20 mL) as a mixture.
Isochratic HPLC conditions of 0.20 to 1.0 mL/min of 0.5 to 1.0 mM
(NHJ 2HP0 4 were used. Data was recorded at 260 nm.
Determination of Retention Times for
Polydeoxyadenylic Acid [p(dA)]on SG-2. Solutions of p(dA) 2 _,
were prepared as follows. 5 units of the p(dA) were dissolved in
pipes buffer (5 mM, pH 7.0). The solutions were injected (20 mL)
as a mixture. Isochratic HPLC conditions of 1.0 mL/min of 1.0 M
(NH 4 ) 2HP0 4 and pH 7 . were used. Data was recorded at 260 nm.
Determination of Retention Times for
Polydeoacycytidilic Acid [p(dC)]on SG-2. Solutions of p(dC) 3 . 5
were prepared as follows. Five units of the p(dC) were dissolved
in pipes buffer (5 mM, pH 7.0). The solutions were injected (20
mL) as a mixture. Isochratic HPLC conditions of 0.10 mL/min of 500
mM (NH 4 ) 2HP0 4 and pH 7.0 were used. Data was recorded at 260 nm.
Retention Times of Anionic Species on DEAE Column.
Various anionic species were injected onto the DEAE column
(Rainin)
. They were injected under isochratic condition of 0.5 M
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(NH«) 2HP0 4 at 0.4 mL/min. Retention times were monitored at 210 or
260 nm.
Determination of Column Efficiency of SG-2 . A solution
of benzene (5 mM) was injected (15 mL) under isochratic conditions
of MeOH/H 2 (50:50) and O.lmL/min. Column efficiency, or the
number of theoretical plates is calculated by:
N = 16 (t r / t w )
2
Where, t r is the retention time for benzene, and t w is baseline peak
width .
Determination of Stationary Phase Coverage. The
surface concentration of the sapphyrin on the stationary phase is
calculated by (156)
:
Coverage = <%X x 10 6 ) / { (AM) nlOO [1-%X (MW) / (AM) nlOO] S)
Where %X is the percentage increase in carbon or nitrogen as
determined by elemental analysis. AM is the atomic mass of carbon
or nitrogen. MW is the molecular weight of the bound species, n is
the number of carbon or nitrogen in the bound species. S is the
surface area of the silica gel in m /gm.
Calculation of Energetics. Retention time versus number
of phosphates was plotted for the p(dA), p(dC), and monoadenosine
phosphate series. Retention times were normalized by calculating
capacity factors (157)
:
k' = (t r - t ) /t
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The selectivity , a (158), for one anion over the other:
a = k'j/k'j
The capacity factor is also related to the equilibrium
distribution, K:
k' = K<D
Where <t> is the phase ratio, or ratio of volumes between the
stationary and mobile phases. As K is the ratio of the number of
moles of the solute in the stationary phase and mobile phase, we
can relate K and the Gibbs Free Energy, AG°:
., AGo/RTK = e
Thus, for different peaks we can find the Gibbs Free Energy
difference, AAG°:
kVk' 2 = (e AV/RT)/( e AG 2 ° /RT )
This can be reduced to:
, _, -AAGo/RTIn a = e
We then plot AAG° versus the number of phosphates. From the
resulting straight lines, we can determine free energy per
phosphate.
N- ( t-butylcarbonyl ) -diaminoethane . Di-tert-butyl-
dicarbonate (17.9 mg, 79 mmol) was dissolved in chloroform (200
mL)
. Ethylene diamine (30.0mL, 449 mmol) was added dropwise. The
mixture was stirred at room temperature for 19 h. The solvents were
rotary evaporated. The residue was extracted with sodium carbonate
(100 mL) and dichloromethane (lOOmL) . The aqueous layer was washed
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with dichloromethane (100 ml) . The dichloromethane layers were
combined and evaporated. The yellow oil was subject to column
chromatography with CH 2Cl 2 /methanol (90%:10%). The fraction
containing the protected amine was evaporated and yielded 10.7mg
(83%) of the product. 1H NMR (CDC1 3 ) 8 1.44 (9H,s,CH 3 ), 1.604
(2H,br,CH 2 ), 2.8 (2H, m, CH 2 ) , 3.189 (2H, m, NH 2 ) , 4.893 (1H, br,
NH) . 13C NMR (CDC1 3 ) 8 28.41, 41.834, 43.315, 79.263, 156.21. LRMS
:
161.1 (Calculated for C 7H 17N2 2 : 161.200).
3, 8, 17, 22-Tetraethyl-12- (N-t-
butylcarbonyldiamidoethyl) -2, 7, 13, 18, 23-pentamethyl-
sapphyrin. Sapphyrin mono-acid (39 mg, 0.062 mmoL) was dissolved
in dry dichloromethane (15 mL) . Oxalyl chloride (0.3 mL, 0.6 mmol)
and 4 drops DMF were added. The reaction was stirred under Argon
for 2 h. The solvents were removed in vacuo. The residue was
dissolved in dry dichloromethane (10 mL) . Protected amine (32 mg,
0.2 mmol) in dry dichloromethane (10 mL) and pyridine (0.1 mL) was
slowly added by dropping funnel. The mixture was stirred overnight
under Argon. The solvents were removed by rotary evaporation. The
resulting oily substance was washed with ddH20 and sodium
bicarbonate. After evaporation the product was dissolved in
dichloromethane and purified by column chromatography with
dichloromethane/MeOH (99:1). The dark fraction was evaporated to
give 40 mg (86%) of the protected sapphyrin-amide . 1H NMR: (CDC1 3 )
8 -5.05 (2H, m, NH)
,
-4.75 (3H, br-m, NH) , 1.5 (9H, s, C0 2 (CH 3 ) 3 ),
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2.3 (6H, t, CH 2Ctf3 ), 2.5 (3H, t, CH 2Ctf3 ) , 2.74 (3H, t, CH 2Ctf3 ) , 3.5
(4H, NHCH2CH 2 ), 4.3 (6H, s, CH 3 ) , 4.35 (6H, s, CH 3 ) , 4.45 (3H, s,
CH 3 ), 4.7 (8H, q, Ctf2CH 3 ) , 5.0 (4H, m, CH 2Cff2CONH) , 7.4 (2H, s,
CONtf) 11.5 (1H, s, meso-H) , 11.75 (3H, s, meso-fl) FAB MS m/e (rel.
intensity) 771 (28, [M-l]), 772 (100, [M] ) , 773 (59,[M+1]), 774
(16, [M+2]). 13C NMR (CDC1 3 ) HRMS: 772.4914 (Calculated for
C47H 62N 7 3 : 772.4912) .
Sapphyrin Dimer. The protected sapphyrin-amide (25 mg,
0.032 mmol) was dissolved in dry dichloromethane (1.5 mL) and
trifluoroacetic acid (1.5 mL) . The mixture was stirred under Argon
for 30 min. The mixture was dried in vacuo. To the same flask was
added solid sapphyrin di-acid (30 mg, 0.043 mmol), l-ethyl-3- (3-
dimethylaminopropyl carbodiimide hydrochloride (9 mg, 0.46 mmol),
and hydroxybenzotriazole (6.4 mg, 0.42 mmol). A stir bar was added
and the reaction vessel evacuated and flushed with Argon. Dry DMF
(2 mL) was added by syringe and the reaction mixed overnight at
room temperature. Dry dichloromethane (50 mL) was added and the
solution washed with brine (3x) , and then ddH 2 (3x). The solvent
was removed by rotary evaporation. The product was purified by
column chromatography. The fraction collected was evaporated and
yielded 35 mg (60 %) of the sapphyrin dimer. XH NMR (CDC1 3 , C 5D 5N,
C 6D 6 , CD 3OD, CD 3SOCD 3 , CD 2C1 2 ) HRMS: 1346.846 (Calculated for
C 84H 106N 12O 4 : 1346.838).
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Sapphyrin Dimer-EDTA Conjugate. The tritylated EDTA
ligand (300 mg, 0.43 mmol) was dissolved in dry methanol (10 ml) .
Pearlman's Pd catalyst (200 mg) was added. The reaction was covered
and stirred under Argon for 18 h. The mixture was filtered through
a medium frit and washed with chloroform. The product was purified
by column chromatography with CH 2Cl 2 /MeOH (85:15). Solvents were
removed by rotary evaporation. The EDTA ligand (5 mg, 0.011 mmol),
sapphyrin dimer (8 mg, 0.0059 mmol), EDC (2.5 mg, 0.012 mmol), and
HOBT (2.0 mg, 0.013 mmol) were placed in a flask. The flask was
evacuated and flushed with Argon. Dry DMF (2.0 ml) was added by
syringe. The reaction was stirred 20 h at room temperature. Dry
CH 2C1 2 (50 ml) was added, and the mixture washed with brine (3x)
and ddH 2 (3x) . The product was purified by column chromatography.
After rotary evaporation 6 mg (58 %) of the protected sapphyrin-
dimer-EDTA conjugate were obtained. . *H NMR (CDC1 3 , C 5D 5N, C 6D 6 ,
CD 3OD, CD3SOCD3, CD 2C1 2 ) FAB MS m/e (rel. intensity) 1767 (24,
[M-3]), 1768 (45, [M-2] ) , 1769 (80, [M-l]), 1770 (100, [M] ) , 1771
(93, [M+l]), 1772 (51, [M+2]), 1773 (28, [M+3]). Vis X„aK (CHC1 3 )
(Abs)= 454 (2.39), 624 (0.11), 676 (0.12), 686(sh) (0.12). HRMS
:
1769.111 (Calculated for C 106H 142N 15O 9 : 1769.16).
The protected conjugate (5 mg, 0.0028 mmol) was dissolved in TFA (2
mL) and allowed to stand for 1 hour. The solution was evaporated,
and then washed with CH 2C1 2 (3x) and MeOH(3x). After rotary
evaporation 4.0 mg of the deprotected complex was obtained. H NMR
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(CDC1 3/ C S D 5 N, C 6D 6 , CD3OD, CD3SOCD3, CD 2C1 2 ) Vis XmiX
(MeOH/CHCl 3 , 10:90) (Abs)= 454 (2.24), 622 (0.14), 676 (0.13),
686(sh) (0.13). Vis X raax (5mM Pipes) (Abs)= 454 (0.33), 424
(sh)(0.15), 612 (0.1), 670 (0.1). Vis A,, x (5mM Pipes, 10% Tween)
(Abs)= 454 (0.13), 424 (0.1). FAB MS m/e 1601 (13.51, [M-l]), 1602
(17.45, [M] ) , 1603 (15.43, [M+l]), 1604 (14.62, [M+2]), 1605
(14.28, [M+3]), also on several others 1665 ( [M+63 (Cu) ] ) , and one
1657 ([M+57(Fe)).
Supercoiled DNA Assay: A stock solution of the sapphyrin-
dimer EDTA conjugate (SDE) (1 mM) was prepared in H 2 with 10 %
Tween for solubility. A solution of Fe (II) -SDE was prepared by
adding Fe(NH«) 2 S0 4 (25 mM, 200 mL) to SDE (50 mM, 200 mL) . A
solution of Fe (II) -EDTA was prepared by adding Fe(NH 4 ) 2S0 4 (25 mM,
200 mL) to EDTA (50 mM, 200 mL) . Reactions were set-up in Eppendorf
tubes. To each tube was added pipes buffer (7 mL, 5 mM)
,
dithiothreitol (DTT) (1 mL of 20 mM) , supercoiled DNA, pBR322, (1
mL of 0.357 mg/mL) , and either SDE or EDTA complexed with Fe(II).
The concentrations of the Fe(II) complexes were 25, 12.5, 6.25,
3.12, and 1.61 mM. One tube contained pipes buffer (8 mL, 5 mM)
,
dithiothreitol (DTT) (1 mL of 20 mM) , supercoiled DNA, pBR322, (1
mL of 0.357 mg/mL). The reaction stopped with bromophenol blue (2
mL) after 30 minutes. The reactions were loaded onto a agarose gel
(1 % in TAE) containing ethidium bromide (6 mL) . The gel was run at
80 volts. The results were visualized under a UV lamp.
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Titration of SDE with Calf Thymus DNA. A solution of calf
thymus DNA (1 mg/mL) was prepared in pipes buffer (1 mM) , this is
equivalent to ~3 mM DNA phosphates. A solution of SDE (3 mM) was
prepared in pipes buffer with 10 % Tween for solubility. The SDE
solution was placed in a cuvette (1 mL) . DNA was added from 1 to
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